Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events [ 2011 ] English The Star : Anti-Cancer application

Sunday17 February 2019

The Star : Anti-Cancer application


A Japanese physician and researcher has based his cancer treatment protocol on dendritic cells’ ability to enable selective and effective attack against tumour cells by the body’s own T cells.

SINCE the discovery of dendritic cells by Dr Ralph Steinman in 1973, much research has been carried out to elucidate the basic functional mechanism of dendritic cells.

Many medical research institutes and universities have conducted research in the use of dendritic cells in anti-cancer immunotherapy.

The ability of dendritic cells to enable selective and effective attack against tumour cells by T cells gave rise to great hopes that it would be an ideal cancer treatment.

HITV (Human Initiated Therapeutic Vaccine) therapy was developed by Japan’s Dr Kenichiro Hasumi. He is a researcher physician, specialising in cancer immunotherapy. He has been involved in cancer immunotherapy research for more than 40 years.

His current protocol involves intratumoural injection (injecting directly into the tumour) of immature autologous (from the patient’s own body) dendritic cells in combination with tomotherapy (a type of radiation therapy).

Source record here


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks